Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com covers CROI 2009, Montreal, February 8-11, 2009
  • Email Email
  • Glossary Glossary


Expert CROI Interviews

David Wohl, M.D.A Review of Cardiovascular Disease and HIV: Highlights From CROI 2009
David Wohl, M.D., provides a detailed summary.

Joel Gallant, M.D., M.P.H.Which CROI 2009 Studies Are Most Likely to Impact Clinical Care?
Tune in as Joel Gallant, M.D., M.P.H., walks us through some of the most important findings regarding HIV treatment strategies presented at CROI 2009.

Conference Roundup: A Lively Discussion of CROI 2009's Headlines
Join HIV clinician and researcher Pablo Tebas, M.D., Rob Camp and Bob Munk, as they chat about some of the big stories coming out of CROI 2009.

TheBody.com is an independent Web site not associated with this conference. TheBody.com provides education and information about HIV.

Featured Coverage
Mari Kitahata, M.D., and Jonathan Sterne, M.D. Ever Upward: "When to Start" Debate Turns to CD4+ Cell Count of 500
Dueling studies -- one presented by Mari Kitahata, M.D., the other by Jonathan Sterne, M.D. -- offer strikingly different views on the benefits of HAART initiation at a CD4+ threshhold of 500. However, both appear to solidify the wisdom of starting therapy before CD4+ cell count drops below 350.
Read or listen (22 min.):
More Top Stories:

Latest Additions:



HIV Treatment StrategiesComplications & CoinfectionsTransmission
The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir

Brian Kearney, Pharm.D.Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
Read or listen (22 min.):

More Highlights:

Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals

Jens Lundgren, M.D.The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
Read or listen (20 min.):

More Highlights:

Potentially Infectious Levels of Intermittent HIV Shedding Can Occur in Seminal Fluid Despite Years of Suppressive HAART, Research Suggests

Prameet ShethPrameet Sheth and Anne-Genevieve Marcelin, Pharm.D., Ph.D., offer the latest salvo in the fervent debate triggered by the release of the so-called "Swiss statement" in 2008. These findings suggest that a male patient can experience spontaneous, periodic shedding of HIV into his seminal fluid despite having consistently undetectable viral load levels in his blood.
Read or listen (13 min.):

More Highlights:


About This Conference

The Body's coverage of the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on CROI 2009, please visit the conference's Web site. You may also view the conference program planner online.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

  • Email Email
  • Glossary Glossary